O-0006 - Rainbow: A Global, Phase 3, Double-Blind Study of Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel in the Treatment of Gastric Cancer Following Disease Progression: Western Population Subgroup

Abstract

Introduction: RAINBOW, a global, placebo-controlled, double-blind, phase III trial, demonstrated significant improvements in overall survival (OS) (hazard ratio (HR) 0.807; 95% CI 0.678, 0.962; p = 0.0169), progression-free survival (PFS) (HR 0.635; 95%CI 0.536, 0.752; p < 0.0001), and response rates (ORR 27.9% RAM + PTX;16.1 PTX p= 0.0001) in advanced gastric or GEJ adenocarcinoma patients receiving ramucirumab (RAM), a human IgG1 VEGF receptor 2 targeted antibody, plus paclitaxel (PTX). We present the pre-planned subgroup analysis of Western patients (Region 1).